Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin

Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

1981 • 1,463 citations

Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters

1990 • 805 citations

cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant Rats

1996 • 641 citations

Multidrug resistance: molecular mechanisms and clinical relevance

1997 • 516 citations

Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.

1993 • 508 citations

Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

1995 • 501 citations

Tissue distribution of the multidrug resistance protein.

1996 • 473 citations

Clinical Pharmacokinetics of Doxorubicin

1988 • 388 citations

Biology of the multidrug resistance-associated protein, MRP

1996 • 367 citations

Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with Neuroblastoma

1996 • 321 citations

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

1997 • 281 citations

Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats.

1998 • 265 citations

Clinical trials of agents that reverse multidrug resistance. A literature review

1993 • 227 citations

Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

1998 • 221 citations

Clinical trials of p-glycoprotein reversal in solid tumours

1996 • 210 citations

P-glycoprotein, multidrug resistance and tumor progression

1994 • 194 citations

Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.

1988 • 192 citations

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

1994 • 186 citations

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

1996 • 179 citations

Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.

1995 • 174 citations

In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients

1997 • 167 citations

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers

1996 • 165 citations

Clinical Studies with Modulators of Multidrug Resistance

1995 • 163 citations

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.

1998 • 149 citations

MDR1 gene expression in solid tumours

1996 • 148 citations

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

1998 • 146 citations

99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein

1998 • 141 citations

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

1997 • 134 citations

Cellular and biochemical characterization of VX-710 as a chemosensitizer

1997 • 131 citations

Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.

1997 • 121 citations

Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.

1996 • 118 citations

99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance

1995 • 114 citations

Epirubicin and doxorubicin comparative metabolism and pharmacokinetics

1988 • 108 citations

Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.

1997 • 104 citations

Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.

1997 • 99 citations

Clinical relevance of P-glycoprotein expression in haematological malignancies

1994 • 93 citations

Expression Pattern of MRP in Human Tissues and Adult Solid Tumor Cell Lines

1995 • 93 citations

Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.

1997 • 91 citations

Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420

1999 • 89 citations

Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies

2000 • 83 citations

The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer

1994 • 81 citations

Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer

1996 • 76 citations

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.

1996 • 73 citations

Multidrug resistance in cancer chemotherapy

1994 • 69 citations

P-glycoprotein in Adult Hematologic Malignancies

1995 • 67 citations

Technetium-99m-MIBI uptake in small cell lung cancer.

1998 • 66 citations

Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression

1996 • 61 citations

P-glycoprotein in Adult Solid Tumors: Expression and Prognostic Significance

1995 • 59 citations

Multidrug Resistance in the Laboratory and Clinic

1994 • 52 citations

Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma

1998 • 48 citations

The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion

1996 • 41 citations

Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer

1997 • 38 citations

The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology

1995 • 32 citations

Bile acid inhibition of P-glycoprotein–mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles

1994 • 31 citations

Clinical imaging of multidrug resistance in cancer.

1999 • 24 citations

Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites.

1989 • 11 citations

Therapeutic Approach to Drug Resistant Tumors

1998 • 7 citations

A Phase II study of the safety, pharmacokinetics and efficacy of IncelTM (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC)

1999 • 1 citations